Live Nov 18 · Cohort 3Nov 18, 19:00 MSK — free hands-on AI agents live workshop · Live Cohort 3 starts Nov 23Join Nov 18 Live →Cohort 3 (Nov 23)

Macaque Prices Jump from $3K to $30K, but Export Bans, Not AI, Are to Blame

The lab macaque has gone from $2–3K to more than $30K, and the media says AI is to blame: neural networks generate molecules, pharma sweeps up the monkeys. It sounds neat, but the real cause is more mundane. China banned exports during COVID, and Cambodia, which had ramped up supply from 3–6 thousand to 30 thousand animals, came under fire from the US Department of Justice and shut off the tap as well. So this is a supply collapse.

AI-processed from TG: @disruptors_official (Дизраптор); edited by Hamidun News
Macaque Prices Jump from $3K to $30K, but Export Bans, Not AI, Are to Blame
Source: TG: @disruptors_official (Дизраптор). Collage: Hamidun News.
Listen to article
Article Fact Sheet & Key Figures
ParameterDetails
Primary sourceTG: @disruptors_official (Дизраптор) ↗
Editor-in-Chief
Key metric #1Before COVID, China supplied 60–70% of macaques for the US
Key metric #2In April 2025, the FDA plans to move away from animal testing
Risk for AI biotechmolecules are growing faster than trials

If you follow AI biotech, you've almost certainly seen headlines like "AI drove macaque prices up 700%." It's a convenient story: neural networks spawn thousands of molecules, pharma buys up monkeys, prices soar. The problem is that reality is far more prosaic. And the takeaway is useful for anyone building or investing in AI for drug discovery.

What happened to prices

The long-tailed macaque, which pharma uses for preclinical trials, cost around $2–3K before COVID. In 2023 the price passed $30K and has barely come down since. The US imports roughly 30 thousand monkeys a year, and for a lab, finding an animal has become a quest of its own.

The AI version is also bolstered by the fact that a Palantir co-founder invested in a macaque farm. But that is an inaccuracy: Joe Lonsdale invested personally through his fund, and he plans to breed primates in Georgia. It has little to do with Palantir itself, let alone with neural networks.

The real causes

Not long ago, 60–70% of macaques in the US were imported from China. During COVID, China banned exports. American pharma urgently switched to Cambodia, and Cambodian farms suddenly ramped up supply from 3–6 thousand to 30 thousand monkeys a year.

The problem is that female macaques did not start giving birth to more young as a result. A likely explanation: some of the animals were captured in the jungle and documented as captive-bred. The US Department of Justice took an interest and filed charges, after which Cambodia also closed exports. This is a classic supply collapse, not a surge in demand because of AI.

Where AI could still make a difference

And this is where it gets most interesting. In April 2025, the FDA released a roadmap for phasing out animal testing. It proposes assessing toxicity with AI models and verifying it on organoids and organs-on-chips. If the regulator truly adopts such methods, AI will become the reason fewer macaques are needed.

But there is a catch. Molecule generation is accelerating faster than their validation. Recursion took a molecule to the clinic in 18 months, versus an industry average of 40+ months. For now the regulator still requires primate testing, and while the top of the funnel speeds up, the bottom remains a bottleneck. If this imbalance persists, demand for macaques really will grow.

What this means in practice

First, this is a good example of how a neat cause-and-effect story about AI turns out to be a myth. Before building a pitch or analysis on such a version, check the supply chain and the regulation.

Second, for AI biotech founders the bottleneck is now not molecule generation but validation. The winners will be those who build tools for preclinical work: toxicity models, organoid platforms, simulations. These are exactly what the FDA intends to recognize as an alternative to animals.

Third, there are limitations. The version about wild-caught macaques remains an assumption, not a proven fact. The timeline for when the regulator will actually give up primates is unknown. So plans should account for both scenarios: expensive macaques for a few more years, and a gradual shift to alternative methods.

Story

Key Questions Answered

What happened to prices?

The long-tailed macaque, which pharma uses for preclinical trials, cost around $2–3K before COVID. In 2023 the price passed $30K and has barely come down since. The US imports roughly 30 thousand monkeys a year, and for a lab, finding an animal has become a quest of its own. The AI version is also bolstered by the fact that a Palantir co-founder invested in a macaque farm. But that is an inaccuracy: Joe Lonsdale invested personally through his fund, and he plans to breed primates in Georgia.

What are the key details on The real causes?

Not long ago, 60–70% of macaques in the US were imported from China. During COVID, China banned exports. American pharma urgently switched to Cambodia, and Cambodian farms suddenly ramped up supply from 3–6 thousand to 30 thousand monkeys a year. The problem is that female macaques did not start giving birth to more young as a result. A likely explanation: some of the animals were captured in the jungle and documented as captive-bred.

Where AI could still make a difference?

And this is where it gets most interesting. In April 2025, the FDA released a roadmap for phasing out animal testing. It proposes assessing toxicity with AI models and verifying it on organoids and organs-on-chips. If the regulator truly adopts such methods, AI will become the reason fewer macaques are needed. But there is a catch. Molecule generation is accelerating faster than their validation. Recursion took a molecule to the clinic in 18 months, versus an industry average of 40+ months.

ZK
Zhemal Khamidun — CPO at Alpina Digital, product manager of AlpinaGPT. Building AI products since 2019. Hamidun News is a pet project that grew into a production aggregator with 6,000+ readers.
✦ Unified AI Workspace · Nomad

Test Frontier LLMs & Autonomous Agents in One Workspace

Run Claude Opus 5.5, GPT-6, Gemini 3.1, and DeepSeek side-by-side in Nomad AI (nomadnet.ai) — unified model routing, deep research, and multimodal workflows under one subscription.

Try Nomad AI →Launch Nomad Agent
What do you think?
Loading comments…